Stéphane Bancel, AP Images
October 25, 2021 11:04 AM EDT
Coronavirus

Covid-19 roundup: Mod­er­na says vac­cine pro­duces 'strong' re­sponse in 5- to 11-year-olds; As­pen Phar­ma­care plans to up vac­cine pro­duc­tion in South Africa — re­port

Nicole DeFeudis

Editor

Af­ter see­ing a “ro­bust” im­mune re­sponse in 6- to 11-year-olds dosed with its Covid-19 vac­cine, Mod­er­na says it’s head­ed to the FDA.

The

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

The End­points 2024 win­ners and losers list: Who was up and who was down in bio­phar­ma

Up­dat­ed: No­vo’s 23% weight loss with Ca­griSe­ma falls short of high ex­pec­ta­tions, new tri­al planned

FDA ap­proves Hu­ma­cyte’s lab-grown blood ves­sels in mile­stone for re­gen­er­a­tive med­i­cine

Ac­cel­er­at­ed ap­proval brings Pfiz­er's BRAF in­hibitor to first-line pa­tients

Sofinno­va out­lines $550M fund af­ter IPOs and M&A deals

Califf, on his way out at FDA, pre­dicts agency tug-of-war be­tween Ra­maswamy and RFK Jr.

A service from the Financial Times